LEGEND BIOTECH CORPORA

Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting

03 يونيو 2025 07:45:00 بحسب Nasdaq GlobeNewswire

Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT

22 مايو 2025 14:15:00 بحسب Nasdaq GlobeNewswire

Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

19 مايو 2025 05:00:00 بحسب Nasdaq GlobeNewswire

Legend Biotech Reports First Quarter 2025 Results and Recent Highlights

13 مايو 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results

29 أبريل 2025 05:00:01 بحسب Nasdaq GlobeNewswire

Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

11 مارس 2025 04:00:00 بحسب Nasdaq GlobeNewswire

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2024 Results

25 فبراير 2025 05:00:00 بحسب Nasdaq GlobeNewswire

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

19 ديسمبر 2024 05:01:00 بحسب Nasdaq GlobeNewswire

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

09 ديسمبر 2024 16:35:00 بحسب Nasdaq GlobeNewswire

Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights

12 نوفمبر 2024 04:00:01 بحسب Nasdaq GlobeNewswire

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

07 نوفمبر 2024 04:30:00 بحسب Nasdaq GlobeNewswire

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

05 نوفمبر 2024 06:10:00 بحسب Nasdaq GlobeNewswire

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

04 نوفمبر 2024 04:30:00 بحسب Nasdaq GlobeNewswire

Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results

24 أكتوبر 2024 05:00:01 بحسب Nasdaq GlobeNewswire

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

03 أكتوبر 2024 04:30:00 بحسب Nasdaq GlobeNewswire

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

27 سبتمبر 2024 13:35:00 بحسب Nasdaq GlobeNewswire

Legend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

20 أغسطس 2024 05:00:00 بحسب Nasdaq GlobeNewswire

Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights

09 أغسطس 2024 04:00:00 بحسب Nasdaq GlobeNewswire

Legend Biotech Appoints Peter Salovey, Ph.D., to its Board of Directors

08 أغسطس 2024 13:05:00 بحسب Nasdaq GlobeNewswire

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024

26 يوليو 2024 04:00:00 بحسب Nasdaq GlobeNewswire